ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/CD19
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/CD19
6
trial(s) found.
NCT06137118
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (
SYRUS
)
bispecific T-cell engager,CD19-targeting
B-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06124157
Paed
Phase 2
Recruiting
An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia (
NCI-2023-09214
)
bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05991388
Paed
Phase 2 / Phase 3
Recruiting
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (
Glo-BNHL
)
Carboplatin
Dexamethasone
Etoposide
Ifosfamide
Loncastuximab Tesirine
Odronextamab
Rituximab
alkylating agent
anti-CD19 antibody-drug conjugate
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
cancer therapy
cancer therapy,CD19-targeting
cancer therapy,CD20-targeting
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD19-targeting
immuno-oncology therapy,CD20-targeting
platinum-based antineoplastic agent
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
topoisomerase inhibitor
+ anti-CD19 antibody-drug conjugate
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05327894
Paed
Phase 3
Recruiting
Interfant-21
International Collaborative Treatment Protocol for Infants Under One Year With KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia.
Blinatumomab
Prednisone
bispecific T-cell engager,CD19-targeting
cancer therapy
cancer therapy,CD19-targeting
glucocorticoid
immuno-oncology therapy,CD19-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
+ bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
Mixed phenotype acute leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NA
8011 - Christchurch - Christchurch Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT03601442
Paed
Available
Managed Access Programs for CTL019, Tisagenlecleucel (
CCTL019B2003I
)
autologous CAR-T-cell therapy,CD19-targeting
Leukaemia
Lymphoma
ACTRN12626000900314
Paed
Phase 4
Not yet recruiting
Changes for Australian Paediatric Patients In the Treatment of Acute Lymphoblastic Leukaemia (
CAPITALL
), A comparison study measuring the effectiveness of an alternative treatment schedule incorporating earlier blinatumomab and standard treatment.
bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (4)
Not yet recruiting (1)
Recruitment Country and State
QLD (3)
WA (3)
NSW (3)
VIC (2)
NZ (2)
SA (1)
Phase
Phase 1 / Phase 2 (1)
Phase 2 (1)
Phase 2 / Phase 3 (1)
Phase 3 (1)
Phase 4 (1)
Trial Type
Paed (6)
Cancer Therapy Class
CD19
100%
BCR-ABL1
17%
KIT
17%
PDGFRA
17%
SRC
17%
YES1
17%
CD20
17%
Facility
4101 - South Brisbane - Queensland Children's Hospital (3)
6009 - Perth - Perth Children's Hospital (3)
2145 - Westmead - The Children's Hospital at Westmead (2)
NZ.1023 - Grafton - Starship Children's Hospital (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
2031 - Randwick - Sydney Children's Hospital (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
3168 - Clayton - Monash Children's Hospital (1)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (1)
8011 - Christchurch - Christchurch Children's Hospital
2031 - Randwick - Prince of Wales Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Leukaemia
Acute lymphoblastic leukaemia
Lymphoid leukaemia
Lymphoma
B-cell acute lymphoblastic leukaemia/lymphoma
Non-Hodgkin's lymphoma
Mixed phenotype acute leukaemia
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy